Sökning: WFRF:(Parameswaran S) > Early Failure of Fr...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 05240naa a2200817 4500 | |
001 | oai:DiVA.org:uu-236521 | |
003 | SwePub | |
008 | 141119s2014 | |||||||||||000 ||eng| | |
009 | oai:prod.swepub.kib.ki.se:129910946 | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-2365212 URI |
024 | 7 | a https://doi.org/10.1016/j.bbmt.2014.06.0362 DOI |
024 | 7 | a http://kipublications.ki.se/Default.aspx?queryparsed=id:1299109462 URI |
040 | a (SwePub)uud (SwePub)ki | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Hamadani, Mehdi4 aut |
245 | 1 0 | a Early Failure of Frontline Rituximab-Containing Chemo-immunotherapy in Diffuse Large B Cell Lymphoma Does Not Predict Futility of Autologous Hematopoietic Cell Transplantation |
264 | 1 | b Elsevier BV,c 2014 |
338 | a print2 rdacarrier | |
520 | a The poor prognosis for patients with diffuse large B cell lymphoma (DLBCL) who relapse within 1 year of initial diagnosis after first-line rituximab-based chemo-immunotherapy has created controversy about the role of autologous transplantation (HCT) in this setting. We compared autologous HCT outcomes for chemosensitive DLBCL patients between 2000 and 2011 in 2 cohorts based on time to relapse from diagnosis. The early rituximab failure (ERF) cohort consisted of patients with primary refractory disease or those with first relapse within 1 year of initial diagnosis. The ERF cohort was compared with those relapsing >1 year after initial diagnosis (late rituximab failure [LRF] cohort). ERF and LRF cohorts included 300 and 216 patients, respectively. Nonrelapse mortality (NRM), progression/relapse, progression-free survival (PFS), and overall survival (OS) of ERF versus LRF cohorts at 3 years were 9% (95% confidence interval [CI], 6% to 13%) versus 9% (95% CI, 5% to 13%), 47% (95% CI, 41% to 52%) versus 39% (95% CI, 33% to 46%), 44% (95% CI, 38% to 50%) versus 52% (95% CI, 45% to 59%), and 50% (95% CI, 44% to 56%) versus 67% (95% CI, 60% to 74%), respectively. On multivariate analysis, ERF was not associated with higher NRM (relative risk [RR], 1.31; P = .34). The ERF cohort had a higher risk of treatment failure (progression/relapse or death) (RR, 2.08; P < .001) and overall mortality (RR, 3.75; P < .001) within the first 9 months after autologous HCT. Beyond this period, PFS and OS were not significantly different between the ERF and LRF cohorts. Autologous HCT provides durable disease control to a sizeable subset of DLBCL despite ERF (3-year PFS, 44%) and remains the standard-of-care in chemosensitive DLBCL regardless of the timing of disease relapse. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Medicinska och farmaceutiska grundvetenskaperx Immunologi inom det medicinska området0 (SwePub)301102 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Basic Medicinex Immunology in the medical area0 (SwePub)301102 hsv//eng |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Hematologi0 (SwePub)302022 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Hematology0 (SwePub)302022 hsv//eng |
653 | a Autologous transplantation | |
653 | a Rituximab | |
653 | a Early failure | |
653 | a High-dose therapy | |
653 | a Diffuse large B cell lymphoma | |
653 | a Aggressive lymphoma | |
653 | a Non-Hodgkin lymphoma | |
700 | 1 | a Hari, Parameswaran N.4 aut |
700 | 1 | a Zhang, Ying4 aut |
700 | 1 | a Carreras, Jeanette4 aut |
700 | 1 | a Akpek, Goerguen4 aut |
700 | 1 | a Aljurf, Mahmoud D.4 aut |
700 | 1 | a Ayala, Ernesto4 aut |
700 | 1 | a Bachanova, Veronika4 aut |
700 | 1 | a Chen, Andy I.4 aut |
700 | 1 | a Chen, Yi-Bin4 aut |
700 | 1 | a Costa, Luciano J.4 aut |
700 | 1 | a Fenske, Timothy S.4 aut |
700 | 1 | a Freytes, Cesar O.4 aut |
700 | 1 | a Ganguly, Siddhartha4 aut |
700 | 1 | a Hertzberg, Mark S.4 aut |
700 | 1 | a Holmberg, Leona A.4 aut |
700 | 1 | a Inwards, David J.4 aut |
700 | 1 | a Kamble, Rammurti T.4 aut |
700 | 1 | a Kanfer, Edward J.4 aut |
700 | 1 | a Lazarus, Hillard M.4 aut |
700 | 1 | a Marks, David I.4 aut |
700 | 1 | a Nishihori, Taiga4 aut |
700 | 1 | a Olsson, Richardu Karolinska Institutet,Uppsala universitet,Centrum för klinisk forskning i Sörmland (CKFD)4 aut0 (Swepub:uu)riols677 |
700 | 1 | a Reddy, Nishitha M.4 aut |
700 | 1 | a Rizzieri, David A.4 aut |
700 | 1 | a Savani, Bipin N.4 aut |
700 | 1 | a Solh, Melhem4 aut |
700 | 1 | a Vose, Julie M.4 aut |
700 | 1 | a Wirk, Baldeep4 aut |
700 | 1 | a Maloney, David G.4 aut |
700 | 1 | a Smith, Sonali M.4 aut |
700 | 1 | a Montoto, Silvia4 aut |
700 | 1 | a Saber, Wael4 aut |
710 | 2 | a Uppsala universitetb Centrum för klinisk forskning i Sörmland (CKFD)4 org |
773 | 0 | t Biology of blood and marrow transplantationd : Elsevier BVg 20:11, s. 1729-1736q 20:11<1729-1736x 1083-8791x 1523-6536 |
856 | 4 | u http://www.bbmt.org/article/S1083879114004030/pdf |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-236521 |
856 | 4 8 | u https://doi.org/10.1016/j.bbmt.2014.06.036 |
856 | 4 8 | u http://kipublications.ki.se/Default.aspx?queryparsed=id:129910946 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Kopiera och spara länken för att återkomma till aktuell vy